CN105497794A - 一种降血脂抗血栓温经活络的中药组合物及其制备方法 - Google Patents
一种降血脂抗血栓温经活络的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN105497794A CN105497794A CN201511022080.1A CN201511022080A CN105497794A CN 105497794 A CN105497794 A CN 105497794A CN 201511022080 A CN201511022080 A CN 201511022080A CN 105497794 A CN105497794 A CN 105497794A
- Authority
- CN
- China
- Prior art keywords
- radix
- antithrombotic
- chinese medicine
- medicine composition
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 238000010792 warming Methods 0.000 title claims abstract description 69
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 51
- 230000002785 anti-thrombosis Effects 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000003213 activating effect Effects 0.000 title abstract 4
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 59
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 59
- 241000628997 Flos Species 0.000 claims abstract description 36
- 238000002156 mixing Methods 0.000 claims abstract description 30
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000000843 powder Substances 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229920001353 Dextrin Polymers 0.000 claims abstract description 24
- 239000004375 Dextrin Substances 0.000 claims abstract description 24
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 24
- 229930006000 Sucrose Natural products 0.000 claims abstract description 24
- 235000019425 dextrin Nutrition 0.000 claims abstract description 24
- 239000000706 filtrate Substances 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000007779 soft material Substances 0.000 claims abstract description 12
- 210000004369 blood Anatomy 0.000 claims description 69
- 239000008280 blood Substances 0.000 claims description 69
- 230000001737 promoting effect Effects 0.000 claims description 48
- 239000009636 Huang Qi Substances 0.000 claims description 29
- 239000005720 sucrose Substances 0.000 claims description 22
- 239000008187 granular material Substances 0.000 claims description 19
- 230000033228 biological regulation Effects 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 9
- 238000002386 leaching Methods 0.000 claims description 9
- 238000004321 preservation Methods 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 230000003179 granulation Effects 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 8
- 239000000284 extract Substances 0.000 abstract description 5
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract description 3
- 229940116229 borneol Drugs 0.000 abstract description 3
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract description 3
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract description 3
- 241000045403 Astragalus propinquus Species 0.000 abstract 2
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 2
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 2
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 2
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 2
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 2
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 2
- 244000164480 Curcuma aromatica Species 0.000 abstract 2
- 241000112528 Ligusticum striatum Species 0.000 abstract 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 2
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 abstract 2
- 235000006533 astragalus Nutrition 0.000 abstract 2
- 238000005453 pelletization Methods 0.000 abstract 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 abstract 2
- 229960004793 sucrose Drugs 0.000 abstract 2
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 235000003398 Curcuma aromatica Nutrition 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 210000002216 heart Anatomy 0.000 description 10
- 210000001015 abdomen Anatomy 0.000 description 9
- 201000005577 familial hyperlipidemia Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 229940127219 anticoagulant drug Drugs 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 230000006793 arrhythmia Effects 0.000 description 4
- 206010003119 arrhythmia Diseases 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000000916 dilatatory effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 3
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 3
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 3
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 3
- 229940117916 cinnamic aldehyde Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000001785 ferulic acid Nutrition 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 3
- 229940114124 ferulic acid Drugs 0.000 description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000003119 painkilling effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010042772 syncope Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- -1 4-hydroxyl-3-butyl Chemical group 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 241000913776 Pueraria montana Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003218 coronary vasodilator agent Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000013219 diaphoresis Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000036581 peripheral resistance Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000227129 Aconitum Species 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241001634851 Apaturinae Species 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 235000008440 Crataegus cuneata Nutrition 0.000 description 1
- 244000160089 Crataegus cuneata Species 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 241000244355 Ligusticum Species 0.000 description 1
- YYSRTHIUABRSAB-UHFFFAOYSA-N Neocarthamin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C(O)C2=C1C(=O)CC(C=1C=CC(O)=CC=1)O2 YYSRTHIUABRSAB-UHFFFAOYSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000124449 Paeonia obovata Species 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 235000018992 Prunus glandulosa Nutrition 0.000 description 1
- 240000001619 Prunus glandulosa Species 0.000 description 1
- 235000013999 Prunus japonica Nutrition 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 244000083724 Rhododendron simsii Species 0.000 description 1
- 244000272264 Saussurea lappa Species 0.000 description 1
- 235000006784 Saussurea lappa Nutrition 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid ester group Chemical class C(CCCCCCCCCCC)(=O)O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- UBFTZAGDGOMJQE-SACPXRHSSA-N neocarthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(O)C(O)=CC2=C1C(=O)C[C@@H](C=1C=CC(O)=CC=1)O2 UBFTZAGDGOMJQE-SACPXRHSSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000010023 qingre quyu Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229930183325 senkyunolide Natural products 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种降血脂抗血栓温经活络的中药组合物，其原料包括：川芎、红花、黄芪、三七、桂枝、赤芍、葛根、郁金、木香、山楂、冰片、蔗糖、糊精。本发明还公开了上述降血脂抗血栓温经活络的中药组合物的制备方法，包括如下步骤：S1、制备浸膏：取川芎、红花、黄芪、赤芍、葛根、桂枝、郁金、木香、山楂混匀得到混合物；向混合物中加水，煎煮三次，过滤取滤液，合并三次滤液，浓缩得到浸膏，其中，浸膏的相对密度为1.32-1.35g/ml；S2、制备三七干粉；S3、制粒：将冰片、乙醇、糊精、蔗糖、S1中得到的浸膏、S2中得到的三七干粉混匀，制软材，制粒，干燥，整粒后，混匀得到降血脂抗血栓温经活络的中药组合物。
Description
技术领域
本发明涉及中药技术领域，尤其涉及一种降血脂抗血栓温经活络的中药组合物及其制备方法。
背景技术
高脂血症是中老年人常见的疾病之一，也是倍受关注和严重影响中老年人正常生活的疾病。一般成年人空腹血清中总胆固醇超过5.72mmol/L，甘油三酯超过1.70mmol/L，可诊断为高脂血症，而总胆固醇在5.2-5.7mmol/L者称为边缘性升高。
高脂血症的临床表现主要包括两大方面：1、脂质在真皮内沉积所引起的黄色瘤；2、脂质在血管内皮沉积所引起的动脉粥样硬化，产生冠心病和周围血管病等。多数高脂血症患者并无任何症状和异常体征发现，常常是在进行血液生化检验时被发现的。
传统中医认为，高脂血症属中医的“痰证”、“虚损”、“胸痹”、“眩晕”等范畴。高血脂症病主要是由心、肝、肾功能的阴阳失调，加上感受风、热、毒等外邪侵袭，以及各种因素相互影响所致。高脂血症的病因有素体脾虚痰盛；或胃火素旺，饮食不节，恣食肥甘，痰浊内生；或年老体虚，脏气衰减，阴虚痰滞，终致痰积血瘀，化为脂浊，滞留体内而为病。
现代医学研究认为，高脂血症由极低相对密度脂蛋白产生过多或清除障碍以及极低相对密度脂蛋白转变成低相对密度脂蛋白过多所致。肥胖，糖尿病，酒精过量，肾病综合征或基因缺陷可引起肝脏低相对密度脂蛋白产生过多，低相对密度脂蛋白和总胆固醇增高异常与血高甘油三酯相关联。低相对密度脂蛋白的清除障碍和载脂蛋白B的结构缺陷有关。另外，清除障碍亦可能由于低相对密度脂蛋白受体数量减少或功能异常、活力降低，这可能是基因或饮食因素所致。低相对密度脂蛋白受体蛋白结构的分子缺陷是低相对密度脂蛋白受体功能异常常见的遗传学原因。
血脂主要是指血清中的胆固醇和甘油三酯。无论是胆固醇含量增高，还是甘油三酯的含量增高，或是两者皆增高，统称为高脂血症。高脂血症分为：1、高胆固醇血症，血清总胆固醇＞5.72mmol/l，甘油三酯＜1.70mmol/l；2、高甘油三脂血症，血清甘油三酯＞1.70mmol/l，总胆固醇＜5.72mmol/l；3、混合型高脂血症，血清总胆固醇＞5.27mmol/l，甘油三酯＞1.70mmol/l；4、低相对密度脂蛋白血症，血清高相对密度脂蛋白-胆固醇含量降低＜9.0mmol/l。
目前，市场上的降脂类产品种类繁多，以他汀类的西药为主，这类西药见效快，但是高血脂症是一种慢性病，需要长期服用药物，长期服用西药容易引起肝功能受损，谷丙转氨酶升高，尿素氮升高，对人体产生不良影响，且对容易对药物产生依赖性。中药无毒副作用，可以长期服用，更适合用于治疗高血脂这一类的慢性病，另外高血脂还容易引起动脉粥样硬化、血栓等。因此需要提供一种降血脂、抗血栓的中药。
发明内容
基于背景技术存在的技术问题，本发明提出了一种降血脂抗血栓温经活络的中药组合物及其制备方法，本发明降血脂、抗血栓、温经活络。
本发明提出的一种降血脂抗血栓温经活络的中药组合物，其原料包括：川芎、红花、黄芪、三七、桂枝、赤芍、葛根、郁金、木香、山楂、冰片、蔗糖、糊精。
川芎，别名为芎藭、小叶川芎、山鞠穷、香果、贯芎、抚芎、台芎、西芎、马衔等，为伞形科植物川芎的干燥根茎。味辛，性温。归肝、胆、心包经。能活血行气，祛风止痛，辛温行散，为“血中之气药”，祛瘀止痛。主治安抚神经，正头风头痛，症瘕腹痛，胸胁刺痛，跌扑肿痛，头痛，风湿痹痛。含有挥发油、阿魏酸、4-羟基-3-丁基酽内酯、川芎酽内酯、藁本内酯、川芎嗪、川芎酚、瑟丹酸等成分，其中，川芎嗪可以解除肾上腺素、氯化钾引起的血管平滑肌痉挛，扩张冠状血管、增加冠脉血流量，对抗垂体后叶素引起的心肌缺血缺氧，减轻结扎冠脉引起的心肌梗死病变程度，扩张脑血管、易透过血脑屏障、脑内分布较多，抑制血小板聚集，改善微循环；阿魏酸可以增加冠脉流量，抑制主动脉收缩，抑制血小板聚集。
红花，别名为草红花、红蓝花、刺红花等，为菊科植物红花的干燥花。味辛，性温。归心经。能活血通经，散瘀止痛，辛散温通，活血而畅通经脉，散瘀。主治经闭，痛经，恶露不行，症瘕痞块，跌扑损伤，疮疡肿痛。含红花甙、新红花甙、红花醌甙、红花多糖、棕榈酸、肉桂酸、月桂酸等成分。红花具有轻度兴奋心脏、降低冠脉阻力、增加冠脉流量和心肌营养性血流量的作用，保护和改善心肌缺血，缩小心肌梗死范围，能抑制血小板聚集，增强纤维蛋白溶解，降低全血粘度，还具有抗炎作用；红黄色素分离物能对抗心律失常，扩张周围血管，降低血压，对中枢神经系统有镇痛、镇静和抗惊厥作用，具有免疫抑制作用；红花苷能显著提高耐缺氧能力，对缺血乏氧性脑病有保护作用。红花能降低冠脉阻力，抗血栓、降血脂。
黄芪，别名为绵芪、绵黄芪、黄耆等，为豆科草本植物蒙古黄芪、膜荚黄芪的根。味甘，性微温；入肺、脾、肝、肾经。能甘补温通，善补气行滞，促进血行，益气固表，敛汗固脱，托疮生肌，利水消肿。主治气虚乏力，中气下陷，久泻脱肛，便血崩漏，表虚自汗，痈疽难溃，久溃不敛，血虚萎黄，内热消渴，慢性肾炎，蛋白尿，糖尿病等。
三七，别名为田七、滇七、参三七、汉三七、山漆、金不换等，为五加科植物三七的根。味甘、苦，性温；入胃、肝经。能苦泄温通甘补，活血化瘀，散瘀止血，消肿定痛。主治咯血，吐血，衄血，便血，崩漏，外伤出血，胸腹剌痛，跌扑肿痛。三七能止血，抗血栓，促进造血，降低心肌收缩力、减慢心率、扩张外周血管、降低外周阻力、抗心肌缺血、抗心律失常，促进蛋白质、核糖核酸(RNA)、脱氧核糖核酸(DNA)合成从而强身健体，促进血液细胞新陈代谢、平衡调节血液细胞，双向调节中枢神经、提高脑力、增强学习和记忆能力；增强机体免疫功能、抗肿瘤，延缓衰老、双向调节血糖、降低血脂、胆固醇、抑制动脉硬化。
桂枝，别名为柳桂等，为樟科常绿乔木植物肉桂的干燥嫩枝。味辛、甘，性温；入心、肺、膀胱经；能镇静作用、助阳、温经活络、发汗解肌。主治风寒表证，肩背肢节酸疼，胸痹痰饮，经闭症瘕。含有桂皮油、桂皮醛、桂皮酸钠、挥发油等成分，桂皮油能扩张血管、调节血液循环、使血液流向体表，桂皮醛和桂皮酸钠能使皮肤血管扩张、散热增加、促进发汗、提高痛阈值，桂皮醛还具有镇静、抗惊厥的作用，挥发油具有抗炎、抗过敏的作用，桂枝还具有抗菌抗病毒的作用。
赤芍，别名为山芍药、草芍药、木芍药、赤芍药、红芍药等，为毛茛科植物芍药或川赤芍的干燥根。味苦，性寒，入肝经。能清热凉血，散瘀止痛，清泄行散。主治温毒发斑，吐血衄血，目赤肿痛，肝郁胁痛，经闭痛经，症瘕腹痛，跌扑损伤，痈肿疮疡，清肝火，除血，活血化瘀。
葛根，别名为葛藤、粉葛、干葛、葛麻藤、甘葛、葛麻茹、葛于根等，为豆科植物野葛或甘葛藤的干燥根。味辛、甘，性平；入胃、脾经。能解肌退热，解热镇静，扩张冠状动脉，改善脑循环，改善心脏。主治伤寒、温热头痛项强、烦热消渴、泄泻、痢疾、癍疹不透、高血压、心绞痛、耳聋。葛根能营养心肌，扩张血管，降糖降脂，防治心肌缺血，心肌梗死，心律失常，高血压，动脉硬化、高血糖，高血脂等病症。
郁金，别名为玉金、白丝郁金、马蒁、黄郁、五帝足、乌头等，为姜科植物郁金的块根。味辛、苦，性凉。入心、胆、肝经。能行气化瘀、清心解郁、利胆退黄、活血凉血、行气止痛。含有挥发油等成分。主治经闭痛经、胸腹胀痛、刺痛、热病神昏、癫痫发狂、黄疸尿赤。郁金有保护肝细胞、促进肝细胞再生、去脂和抑制肝细胞纤维化的作用，能对抗肝脏毒性病变。
木香，别名为云木香、广木香、蜜香、青木香、五香、五木香、南木香等，为菊科植物川木香的根。味辛、苦，性温。入肺、脾、肝经。能行气止痛、调中导滞、行苦泄温通、调畅气血。主治胞哎吐泄泻、脘腹胀痛，肠鸣腹泻，里急后重，两胁不舒，肝胆疼痛。
山楂，别名为粱梅、鼠查、赤枣子、山里红果、柿楂子、映山红果、小叶山楂、红果、棠棣、绿梨等，为蔷薇科植物山里红或山楂的干燥成熟果实。味酸、甘，性温。入胃、脾、肝经。能开胃消食、化滞消积、化痰行气、活血消滞、化瘀降脂。主治肉食滞积、症瘕积聚、腹胀痞满、瘀阻腹痛、痰饮、泄泻、肠风下血。山楂对各种痢疾杆菌及绿脓杆菌、大肠杆菌、金黄色球菌、炭疽杆菌等均有明显的抑制作用，还有治疗绦虫的作用。山楂能防治心血管疾病，具有扩张血管、增加冠脉血流量、改善心脏活力、兴奋中枢神经系统、降低血压和胆固醇、软化血管及利尿和镇静作用，能用于治疗高血压和高血脂症。
冰片，别名为合成龙脑、梅片、艾粉、结片等，是龙脑香科植物龙脑香的树脂和挥发油加工品提取获得的结晶。味辛、苦，性凉，入心、肺经。能开窍醒神、清热止痛。主治热病神昏、痉厥，中风痰厥，气郁暴厥，中恶昏迷，目赤，口疮，咽喉肿痛，耳道流脓。
优选地，其原料按重量份包括：川芎10-15份，红花4-8份，黄芪15-25份，三七5-7份，桂枝4-8份，赤芍5-10份，葛根2-5份，郁金3-9份，木香3-6份，山楂3-10份，冰片0.15-0.35份，蔗糖25-55份，糊精10-35份。
优选地，川芎、红花、黄芪、三七、桂枝的重量比为11-13：6-8：16-20：5-6：5-7。
优选地，其原料按重量份包括：川芎11-13份，红花6-8份，黄芪16-20份，三七5-6份，桂枝5-7份，赤芍6-8份，葛根4-5份，郁金4-8份，木香3-4份，山楂4-8份，冰片0.2-0.3份，蔗糖30-50份，糊精15-30份。
优选地，其原料按重量份包括：川芎11份，红花8份，黄芪20份，三七5份，桂枝5份，赤芍8份，葛根5份，郁金8份，木香4份，山楂8份，冰片0.2份，蔗糖40份，糊精25份。
本发明还提出了上述降血脂抗血栓温经活络的中药组合物的制备方法，包括如下步骤：
S1、制备浸膏：取川芎、红花、黄芪、赤芍、葛根、桂枝、郁金、木香、山楂混匀得到混合物；向混合物中加水，煎煮三次，过滤取滤液，合并三次滤液，浓缩得到浸膏，其中，浸膏的相对密度为1.32-1.35g/ml；
S2、制备三七干粉：取三七高压蒸汽灭菌，冷却至室温，调节真空度，升温，保温干燥，粉碎得到三七干粉；
S3、制粒：将冰片、乙醇、糊精、蔗糖、S1中得到的浸膏、S2中得到的三七干粉混匀，制软材，制粒，干燥，整粒后，混匀得到降血脂抗血栓温经活络的中药组合物。
优选地，在S1中，取川芎、红花、黄芪、赤芍、葛根、桂枝、郁金、木香、山楂混匀得到混合物；向混合物中加水，调节蒸汽压力为0.2-0.3MPa，煎煮三次，过滤取滤液，合并三次滤液，升温至80-90℃，调节真空度至0.02-0.04MPa，蒸汽压力至0.05-0.1MPa，浓缩得到浸膏，其中，浸膏的相对密度为1.32-1.35g/ml。
优选地，在S1中，一次煎煮用水量为混合物重的7-9倍，煎煮3-4h，二次煎煮和三次煎煮的用水量均为混合物重的5-7倍，二次煎煮和三次煎煮均煎煮2-3h，浸膏的相对密度是在温度为60-70℃的条件下检测的。
优选地，在S2中，取三七，升温至110-120℃，高压蒸汽灭菌30-50min，冷却至室温，调节真空度为0.06-0.07MPa，升温至70-90℃，保温干燥2-3h，粉碎至80-120目得到三七干粉。
优选地，在S3中，将冰片、乙醇、糊精、80-100目蔗糖、S1中得到的浸膏、S2中得到的三七干粉混匀，制软材，用16目筛网制粒，升温至60-80℃干燥0.5-1.5h，依次用10目筛网、40目筛网整粒后，混匀得到降血脂抗血栓温经活络的中药组合物。
上述中药组合物的剂型是颗粒剂，其制剂规格是12g/袋。
上述S1中，浸膏在温度≤4℃的条件下，贮藏时间不超过3个月。
上述S3中，乙醇的作用是制软材，制成的软材达到轻握成团，一触即散的状态即可，不规定乙醇的具体用量，根据具体操作确定其用量。
中医理论认为高血脂症病主要是由心、肝、肾功能的阴阳失调，加上感受风、热、毒等外邪侵袭，以及各种因素相互影响所致。因此平肝潜阳，理气活血，滋阴养肾，清热祛瘀是治疗高血脂症的有效途径。本发明以川芎为君药，活血行气，祛瘀止痛，辛温行散；以红花、黄芪、三七、桂枝为臣药，辅助君药活血通经，祛瘀止痛，还能温通甘补、温经活络；以赤芍、葛根、郁金、木香、山楂为佐药，赤芍、葛根、郁金可以缓解君药和臣药的温热，清热散瘀，各味佐药还可进一步促进君药和臣药行气化瘀，并且可以和脾胃、疏肝；以冰片为使药，开窍醒神、清热止痛；另外，川芎中含有川芎嗪可以解除血管平滑肌痉挛，扩张冠状血管、增加冠脉血流量，抑制血小板聚集，改善微循环；川芎中含有阿魏酸可以增加冠脉流量，抑制主动脉收缩，抑制血小板聚集；红花能降低冠脉阻力，抗血栓、降血脂；三七能抗血栓，促进造血，扩张外周血管、降低外周阻力，双向调节血糖、降低血脂、胆固醇、抑制动脉硬化；葛根能扩张血管，降糖降脂，防治心肌梗死，心律失常，高血压，动脉硬化、高血脂等病症；郁金能保护肝细胞、促进肝细胞再生、去脂和抑制肝细胞纤维化；山楂能防治心血管疾病，降低血压和胆固醇，能用于治疗高血压和高血脂症；上述诸药相互配合辛通泄降，共奏活血化瘀、通经活络之功，故善治疗瘀血阻络所致的中风，血脂增高，脑血栓引起的精神呆滞，舌质发硬，言语迟涩，发音不清，手足发凉，活动疼痛。
具体实施方式
下面，通过具体实施例对本发明的技术方案进行详细说明。
实施例1
一种降血脂抗血栓温经活络的中药组合物，其原料按重量份包括：川芎10份，红花8份，黄芪15份，三七7份，桂枝4份，赤芍10份，葛根2份，郁金9份，木香3份，山楂10份，冰片0.15份，蔗糖55份，糊精10份。
上述降血脂抗血栓温经活络的中药组合物的制备方法，包括如下步骤：
S1、制备浸膏：取川芎、红花、黄芪、赤芍、葛根、桂枝、郁金、木香、山楂混匀得到混合物；向混合物中加水，调节蒸汽压力为0.3MPa，煎煮三次，过滤取滤液，合并三次滤液，升温至80℃，调节真空度至0.04MPa，蒸汽压力至0.05MPa，浓缩得到浸膏，其中，浸膏的相对密度为1.35g/ml，一次煎煮用水量为混合物重的7倍，煎煮4h，二次煎煮和三次煎煮的用水量均匀为混合物重的5倍，二次煎煮和三次煎煮均煎煮3h，浸膏的相对密度是在温度为60℃的条件下检测的；
S2、制备三七干粉：取三七，升温至120℃，高压蒸汽灭菌30min，冷却至室温，调节真空度为0.07MPa，升温至70℃，保温干燥3h，粉碎至80目得到三七干粉；
S3、制粒：将冰片、乙醇、糊精、100目蔗糖、S1中得到的浸膏、S2中得到的三七干粉混匀，制软材，用16目筛网制粒，升温至60℃干燥4h，依次用10目筛网、40目筛网整粒后，混匀得到降血脂抗血栓温经活络的中药组合物。
实施例2
一种降血脂抗血栓温经活络的中药组合物，其原料按重量份包括：川芎15份，红花4份，黄芪25份，三七5份，桂枝8份，赤芍5份，葛根5份，郁金3份，木香6份，山楂3份，冰片0.35份，蔗糖25份，糊精35份。
上述降血脂抗血栓温经活络的中药组合物的制备方法，包括如下步骤：
S1、制备浸膏：取川芎、红花、黄芪、赤芍、葛根、桂枝、郁金、木香、山楂混匀得到混合物；向混合物中加水，调节蒸汽压力为0.2MPa，煎煮三次，过滤取滤液，合并三次滤液，升温至90℃，调节真空度至0.02MPa，蒸汽压力至0.1MPa，浓缩得到浸膏，其中，浸膏的相对密度为1.32g/ml，一次煎煮用水量为混合物重的9倍，煎煮3h，二次煎煮和三次煎煮的用水量均匀为混合物重的7倍，二次煎煮和三次煎煮均煎煮2h，浸膏的相对密度是在温度为70℃的条件下检测的；
S2、制备三七干粉：取三七，升温至110℃，高压蒸汽灭菌50min，冷却至室温，调节真空度为0.06MPa，升温至90℃，保温干燥2h，粉碎至120目得到三七干粉；
S3、制粒：将冰片、乙醇、糊精、80目蔗糖、S1中得到的浸膏、S2中得到的三七干粉混匀，制软材，用16目筛网制粒，升温至80℃干燥2h，依次用10目筛网、40目筛网整粒后，混匀得到降血脂抗血栓温经活络的中药组合物。
实施例3
一种降血脂抗血栓温经活络的中药组合物，其原料按重量份包括：川芎12份，红花7份，黄芪16份，三七6份，桂枝6份，赤芍7份，葛根4份，郁金7份，木香3份，山楂7份，冰片0.25份，蔗糖50份，糊精15份。
上述降血脂抗血栓温经活络的中药组合物的制备方法，包括如下步骤：
S1、制备浸膏：取川芎、红花、黄芪、赤芍、葛根、桂枝、郁金、木香、山楂混匀得到混合物；向混合物中加水，调节蒸汽压力为0.28MPa，煎煮三次，过滤取滤液，合并三次滤液，升温至82℃，调节真空度至0.035MPa，蒸汽压力至0.06MPa，浓缩得到浸膏，其中，浸膏的相对密度为1.34g/ml，一次煎煮用水量为混合物重的7.5倍，煎煮3.7h，二次煎煮和三次煎煮的用水量均匀为混合物重的5.5倍，二次煎煮和三次煎煮均煎煮2.7h，浸膏的相对密度是在温度为63℃的条件下检测的；
S2、制备三七干粉：取三七，升温至118℃，高压蒸汽灭菌35min，冷却至室温，调节真空度为0.068MPa，升温至75℃，保温干燥2.7h，粉碎至80目得到三七干粉；
S3、制粒：将冰片、乙醇、糊精、100目蔗糖、S1中得到的浸膏、S2中得到的三七干粉混匀，制软材，用16目筛网制粒，升温至65℃干燥3.5h，依次用10目筛网、40目筛网整粒后，混匀得到降血脂抗血栓温经活络的中药组合物。
实施例4
一种降血脂抗血栓温经活络的中药组合物，其原料按重量份包括：川芎13份，红花6份，黄芪18份，三七5.5份，桂枝7份，赤芍6份，葛根4.5份，郁金4份，木香3.5份，山楂4份，冰片0.3份，蔗糖30份，糊精30份。
上述降血脂抗血栓温经活络的中药组合物的制备方法，包括如下步骤：
S1、制备浸膏：取川芎、红花、黄芪、赤芍、葛根、桂枝、郁金、木香、山楂混匀得到混合物；向混合物中加水，调节蒸汽压力为0.22MPa，煎煮三次，过滤取滤液，合并三次滤液，升温至88℃，调节真空度至0.025MPa，蒸汽压力至0.08MPa，浓缩得到浸膏，其中，浸膏的相对密度为1.33g/ml，一次煎煮用水量为混合物重的8.5倍，煎煮3.3h，二次煎煮和三次煎煮的用水量均匀为混合物重的6.5倍，二次煎煮和三次煎煮均煎煮2.3h，浸膏的相对密度是在温度为67℃的条件下检测的；
S2、制备三七干粉：取三七，升温至112℃，高压蒸汽灭菌45min，冷却至室温，调节真空度为0.062MPa，升温至85℃，保温干燥2.3h，粉碎至120目得到三七干粉；
S3、制粒：将冰片、乙醇、糊精、80目蔗糖、S1中得到的浸膏、S2中得到的三七干粉混匀，制软材，用16目筛网制粒，升温至75℃干燥2.5h，依次用10目筛网、40目筛网整粒后，混匀得到降血脂抗血栓温经活络的中药组合物。
实施例5
一种降血脂抗血栓温经活络的中药组合物，其原料按重量份包括：川芎11份，红花8份，黄芪20份，三七5份，桂枝5份，赤芍8份，葛根5份，郁金8份，木香4份，山楂8份，冰片0.2份，蔗糖40份，糊精25份。
上述降血脂抗血栓温经活络的中药组合物的制备方法，包括如下步骤：
S1、制备浸膏：取川芎、红花、黄芪、赤芍、葛根、桂枝、郁金、木香、山楂混匀得到混合物；向混合物中加水，调节蒸汽压力为0.25MPa，煎煮三次，过滤取滤液，合并三次滤液，升温至85℃，调节真空度至0.03MPa，蒸汽压力至0.07MPa，浓缩得到浸膏，其中，浸膏的相对密度为1.335g/ml，一次煎煮用水量为混合物重的8倍，煎煮3.5h，二次煎煮和三次煎煮的用水量均匀为混合物重的6倍，二次煎煮和三次煎煮均煎煮2.5h，浸膏的相对密度是在温度为65℃的条件下检测的；
S2、制备三七干粉：取三七，升温至115℃，高压蒸汽灭菌40min，冷却至室温，调节真空度为0.065MPa，升温至80℃，保温干燥2.5h，粉碎至100目得到三七干粉；
S3、制粒：将冰片、乙醇、糊精、80目蔗糖、S1中得到的浸膏、S2中得到的三七干粉混匀，制软材，用16目筛网制粒，升温至70℃干燥3h，依次用10目筛网、40目筛网整粒后，混匀得到降血脂抗血栓温经活络的中药组合物。
试验例1
选用体重为200-220g，7-9周龄，雌雄各半的大鼠60只。平均分为7组。试验1组10只，其中雌鼠4只，雄鼠6只，平均年龄8.5±0.1周龄，平均体重210±1g；试验2组10只，其中雌鼠5只，雄鼠5只，平均年龄8.2±0.3周龄，平均体重211±0.6g；试验3组10只，其中雌鼠6只，雄鼠4只，平均年龄8±0.2周龄，平均体重210±1.5g；试验4组10只，其中雌鼠5只，雄鼠5只，平均年龄8.1±0.1周龄，平均体重212±0.3g；试验5组10只，其中雌鼠5只，雄鼠5只，平均年龄7.9±0.3周龄，平均体重211±1.3g；对照1组10只，其中雌鼠5只，雄鼠5只，平均年龄8.1±0.1周龄，平均体重210±0.1g；对照2组10只，其中雌鼠5只，雄鼠5只，平均年龄8.2±0.2周龄，平均体重210±0.2g；7组间性别、年龄、体重方面，经统计学处理，无明显组间差异(P＞0.05)。
7组大鼠均在温度为25±2℃，湿度为40-60％，12h明暗循环的条件下饲养，其中，试验1-5组每天依次喂养2g实施例1-5和1kg高脂饲料，自由饮水；对照1组每天喂养1kg高脂饲料，自由饮水；对照2组每天喂养1kg普通饲料，自由饮水；连续喂养30天后，在第31天清晨空腹情况下，于大鼠颈动脉采血检测，检测结果如下：
由上表可以看出，饲喂高脂饲料的试验1-5组和对照1组的TC、TG、LDL-C均高于饲喂普通饲料的对照2组，饲喂本发明的试验1-5组的TC、TG、LDL-C均低于对照1组，试验1-5组的HDL-C均高于对照1组，由此可以看出本发明具有降血脂的作用。
试验例2
选用体重为200-220g，7-9周龄，雌雄各半的大鼠60只。平均分为6组。试验Ⅰ组10只，其中雌鼠6只，雄鼠4只，平均年龄8.6±0.2周龄，平均体重213±0.5g；试验Ⅱ组10只，其中雌鼠4只，雄鼠6只，平均年龄8.3±0.4周龄，平均体重210±0.7g；试验Ⅲ组10只，其中雌鼠5只，雄鼠5只，平均年龄8.1±0.3周龄，平均体重211±0.8g；试验Ⅳ组10只，其中雌鼠5只，雄鼠5只，平均年龄8.1±0.5周龄，平均体重210±0.6g；试验Ⅴ组10只，其中雌鼠4只，雄鼠6只，平均年龄8.2±0.1周龄，平均体重210±0.8g；空白组10只，其中雌鼠5只，雄鼠5只，平均年龄8.1±0.3周龄，平均体重211±0.2g；6组间性别、年龄、体重方面，经统计学处理，无明显组间差异(P＞0.05)。
6组大鼠均在温度为25±2℃，湿度为40-60％，12h明暗循环的条件下饲养，其中，试验Ⅰ-Ⅴ组每天依次喂养2g实施例1-5和1kg普通饲料，自由饮水；空白组每天喂养1kg普通饲料，自由饮水；连续喂养30天，各组大鼠于末次喂食后1h，进行麻醉，开腹分离下腔静脉，在左肾静脉下方用线结扎，2h后，于结扎处下2cm处结扎血管，阻断血流，记录血栓形成率，取出血栓，测血栓长度和血栓湿重。检测结果如下：
其中，血栓形成率(％)＝各组形成血栓的个数/各组总受试个数×100％
由上表可以看出，本发明能大大降低大鼠血栓湿重，减少血栓形成。
以上所述，仅为本发明较佳的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，根据本发明的技术方案及其发明构思加以等同替换或改变，都应涵盖在本发明的保护范围之内。
Claims (10)
1.一种降血脂抗血栓温经活络的中药组合物，其特征在于，其原料包括：川芎、红花、黄芪、三七、桂枝、赤芍、葛根、郁金、木香、山楂、冰片、蔗糖、糊精。
2.根据权利要求1所述降血脂抗血栓温经活络的中药组合物，其特征在于，其原料按重量份包括：川芎10-15份，红花4-8份，黄芪15-25份，三七5-7份，桂枝4-8份，赤芍5-10份，葛根2-5份，郁金3-9份，木香3-6份，山楂3-10份，冰片0.15-0.35份，蔗糖25-55份，糊精10-35份。
3.根据权利要求1或2项所述降血脂抗血栓温经活络的中药组合物，其特征在于，川芎、红花、黄芪、三七、桂枝的重量比为11-13：6-8：16-20：5-6：5-7。
4.根据权利要求1-3任一项所述降血脂抗血栓温经活络的中药组合物，其特征在于，其原料按重量份包括：川芎11-13份，红花6-8份，黄芪16-20份，三七5-6份，桂枝5-7份，赤芍6-8份，葛根4-5份，郁金4-8份，木香3-4份，山楂4-8份，冰片0.2-0.3份，蔗糖30-50份，糊精15-30份。
5.根据权利要求1-4任一项所述降血脂抗血栓温经活络的中药组合物，其特征在于，其原料按重量份包括：川芎11份，红花8份，黄芪20份，三七5份，桂枝5份，赤芍8份，葛根5份，郁金8份，木香4份，山楂8份，冰片0.2份，蔗糖40份，糊精25份。
6.一种如权利要求1-5任一项所述降血脂抗血栓温经活络的中药组合物的制备方法，其特征在于，包括如下步骤：
S1、制备浸膏：取川芎、红花、黄芪、赤芍、葛根、桂枝、郁金、木香、山楂混匀得到混合物；向混合物中加水，煎煮三次，过滤取滤液，合并三次滤液，浓缩得到浸膏，其中，浸膏的相对密度为1.32-1.35g/ml；
S2、制备三七干粉：取三七高压蒸汽灭菌，冷却至室温，调节真空度，升温，保温干燥，粉碎得到三七干粉；
S3、制粒：将冰片、乙醇、糊精、蔗糖、S1中得到的浸膏、S2中得到的三七干粉混匀，制软材，制粒，干燥，整粒后，混匀得到降血脂抗血栓温经活络的中药组合物。
7.根据权利要求6所述降血脂抗血栓温经活络的中药组合物的制备方法，其特征在于，在S1中，取川芎、红花、黄芪、赤芍、葛根、桂枝、郁金、木香、山楂混匀得到混合物；向混合物中加水，调节蒸汽压力为0.2-0.3MPa，煎煮三次，过滤取滤液，合并三次滤液，升温至80-90℃，调节真空度至0.02-0.04MPa，蒸汽压力至0.05-0.1MPa，浓缩得到浸膏，其中，浸膏的相对密度为1.32-1.35g/ml。
8.根据权利要求6或7所述降血脂抗血栓温经活络的中药组合物的制备方法，其特征在于，在S1中，一次煎煮用水量为混合物重的7-9倍，煎煮3-4h，二次煎煮和三次煎煮的用水量均为混合物重的5-7倍，二次煎煮和三次煎煮均煎煮2-3h，浸膏的相对密度是在温度为60-70℃的条件下检测的。
9.根据权利要求6-8任一项所述降血脂抗血栓温经活络的中药组合物的制备方法，其特征在于，在S2中，取三七，升温至110-120℃，高压蒸汽灭菌30-50min，冷却至室温，调节真空度为0.06-0.07MPa，升温至70-90℃，保温干燥2-3h，粉碎至80-120目得到三七干粉。
10.根据权利要求6-9任一项所述降血脂抗血栓温经活络的中药组合物的制备方法，其特征在于，在S3中，将冰片、乙醇、糊精、80-100目蔗糖、S1中得到的浸膏、S2中得到的三七干粉混匀，制软材，用16目筛网制粒，升温至60-80℃干燥0.5-1.5h，依次用10目筛网、40目筛网整粒后，混匀得到降血脂抗血栓温经活络的中药组合物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511022080.1A CN105497794A (zh) | 2015-12-30 | 2015-12-30 | 一种降血脂抗血栓温经活络的中药组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511022080.1A CN105497794A (zh) | 2015-12-30 | 2015-12-30 | 一种降血脂抗血栓温经活络的中药组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105497794A true CN105497794A (zh) | 2016-04-20 |
Family
ID=55706346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511022080.1A Pending CN105497794A (zh) | 2015-12-30 | 2015-12-30 | 一种降血脂抗血栓温经活络的中药组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105497794A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115381876A (zh) * | 2022-09-09 | 2022-11-25 | 云南植物药业有限公司 | 一种舒心降脂的口服制剂及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1541683A (zh) * | 2003-11-05 | 2004-11-03 | 济宁华能制药厂 | 抗血栓芪龙胶囊 |
| CN104547881A (zh) * | 2013-10-16 | 2015-04-29 | 栾晓明 | 一种降血脂的中药 |
| CN104826033A (zh) * | 2015-06-01 | 2015-08-12 | 青岛友诚高新技术有限公司 | 一种治疗冠心病的中药组合物及其制备方法 |
| CN104856968A (zh) * | 2015-05-27 | 2015-08-26 | 韩志强 | 一种具有消栓通络作用的中药片剂及其制备方法 |
-
2015
- 2015-12-30 CN CN201511022080.1A patent/CN105497794A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1541683A (zh) * | 2003-11-05 | 2004-11-03 | 济宁华能制药厂 | 抗血栓芪龙胶囊 |
| CN104547881A (zh) * | 2013-10-16 | 2015-04-29 | 栾晓明 | 一种降血脂的中药 |
| CN104856968A (zh) * | 2015-05-27 | 2015-08-26 | 韩志强 | 一种具有消栓通络作用的中药片剂及其制备方法 |
| CN104826033A (zh) * | 2015-06-01 | 2015-08-12 | 青岛友诚高新技术有限公司 | 一种治疗冠心病的中药组合物及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 王俊美 等: "葛根与消栓通络胶囊治疗椎-基底动脉供血不足疗效观察", 《滨州医学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115381876A (zh) * | 2022-09-09 | 2022-11-25 | 云南植物药业有限公司 | 一种舒心降脂的口服制剂及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103251867B (zh) | 一种治疗糖尿病的中药复方药物及其制备方法 | |
| CN101380129B (zh) | 一种减肥益寿饮品及其生产工艺 | |
| CN103690783B (zh) | 用于治疗糖尿病的中药制剂及其制备方法 | |
| CN102948563A (zh) | 中药减肥保健茶 | |
| CN104491759A (zh) | 一种治疗偏头痛的中药组合物及其制备方法 | |
| CN104083727A (zh) | 一种养肝护肝中药组合物 | |
| CN104904964A (zh) | 一种降糖降脂的罗布麻叶保健茶及其制备方法 | |
| CN105031517A (zh) | 一种降三高的铁皮石斛保健茶及其制备方法 | |
| CN104740541A (zh) | 一种保肝解毒恢复肝功能的保健中药粉 | |
| CN101129588A (zh) | 结膜炎冲剂 | |
| CN103550746A (zh) | 一种治疗心血管疾病的中药制剂 | |
| CN104958445A (zh) | 一种防治风热上攻目赤肿痛的蔓荆子口服液及其制备方法 | |
| CN103719672A (zh) | 一种补益气血药膳粥 | |
| CN101496892B (zh) | 一种治疗心脑血管疾病的口服中成药 | |
| CN103656603A (zh) | 一种用于解酒的中药组合物、制备方法及应用 | |
| CN102847061A (zh) | 一种治疗小儿病毒性心肌炎的中药制剂及其制备方法 | |
| CN105497794A (zh) | 一种降血脂抗血栓温经活络的中药组合物及其制备方法 | |
| CN104645015A (zh) | 一种治疗血管性痴呆的中药复方制剂及其制备方法 | |
| CN103705733B (zh) | 一种治疗心律不齐的中药胶囊及其制备方法 | |
| CN105796971A (zh) | 一种治疗脂肪肝的中药制剂及其制作方法 | |
| CN105616874A (zh) | 治疗肝癌的药物组合及其生产方法 | |
| CN105327181A (zh) | 一种治疗糖尿病的药物组合物 | |
| CN111011852A (zh) | 一种具有保肝功能的人参方便食品的制备方法 | |
| CN103099886A (zh) | 有助于改善肠胃功能的软胶囊及其制备方法 | |
| CN107823291A (zh) | 一种调理糖尿病引起的高血压的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160513 Address after: 454000 Jiaozuo urban and rural integration demonstration area Yuxi Road, Henan Province Applicant after: Jiangsu Pingguang Xinyi (Jiaozuo) Chinese medicine limited company Address before: Xifei River Road Changfeng Shuangfeng Economic Development Zone of Hefei City, Anhui Province, No. 008 231100 Applicant before: PINGGUANG PHARMACEUTICAL CO., LTD. |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160420 |
|
| RJ01 | Rejection of invention patent application after publication |